A G Bosanquet

Summary

Affiliation: University of Bath
Country: UK

Publications

  1. ncbi High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
    Patrick D Thornton
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Ann Hematol 82:759-65. 2003
  2. ncbi Parameters affecting the ex vivo cytotoxic drug sensitivity of human hematopoietic cells
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, School of Postgraduate Medicine, University of Bath, Bath, UK
    J Exp Ther Oncol 2:53-63. 2002
  3. ncbi Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay
    A G Bosanquet
    Bath Cancer Research Unit, School of Postgraduate Medicine, University of Bath, Royal United Hospital, Bath
    Br J Haematol 106:71-7. 1999
  4. ncbi Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay
    A G Bosanquet
    Royal United Hospital, Bath, UK
    Br J Haematol 106:474-6. 1999
  5. ncbi Effect of interleukin-2 on CD95 (Fas/APO-1) expression in fresh chronic lymphocytic leukaemia and mantle cell lymphoma cells: relationship to ex vivo chemoresponse
    A G Bosanquet
    Bath Cancer Research, Wolfson Center, Royal United Hospital, U K
    Anticancer Res 19:5329-34. 1999
  6. ncbi Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia
    A G Bosanquet
    Bath Cancer Research, Wolfson Centre, Royal United Hospital, Bath, UK
    Leukemia 16:1035-44. 2002
  7. ncbi Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP
    A G Bosanquet
    Bath Cancer Research Unit, School of Postgraduate Medicine, University of Bath, Royal United Hospital, UK
    Br J Cancer 76:511-8. 1997
  8. ncbi Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, Bath BA1 3NG, UK
    J Exp Ther Oncol 4:145-54. 2004
  9. ncbi In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis
    Isrid Sturm
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Berlin Buch, Berlin, Germany
    BMC Cancer 5:105. 2005
  10. ncbi Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation
    Isrid Sturm
    Department of Hematology and Oncology, Charite, Campus Virchow Medical Center, Humboldt University, Berlin, Germany
    Int J Cancer 118:2329-36. 2006

Collaborators

Detail Information

Publications10

  1. ncbi High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities
    Patrick D Thornton
    Academic Department of Haematology and Cytogenetics, The Royal Marsden NHS Trust, London, UK
    Ann Hematol 82:759-65. 2003
    ..This study demonstrates that HDMP alone or in combination with other agents is a useful treatment strategy in refractory CLL including patients with p53 abnormalities...
  2. ncbi Parameters affecting the ex vivo cytotoxic drug sensitivity of human hematopoietic cells
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, School of Postgraduate Medicine, University of Bath, Bath, UK
    J Exp Ther Oncol 2:53-63. 2002
    ..Drug therapeutic index results are a valuable tool in identifying novel cytotoxic agents and individually tailored chemotherapy regimens...
  3. ncbi Prognosis for fludarabine therapy of chronic lymphocytic leukaemia based on ex vivo drug response by DiSC assay
    A G Bosanquet
    Bath Cancer Research Unit, School of Postgraduate Medicine, University of Bath, Royal United Hospital, Bath
    Br J Haematol 106:71-7. 1999
    ..Disease management, response, survival and use of financial resources might be significantly improved if therapy choice in CLL patients was guided by DiSC assay...
  4. ncbi Response to cladribine in previously treated patients with chronic lymphocytic leukaemia identified by ex vivo assessment of drug sensitivity by DiSC assay
    A G Bosanquet
    Royal United Hospital, Bath, UK
    Br J Haematol 106:474-6. 1999
    ..5 years, median survival 3.37 years) and two had a >70% fall in lymphocytes: six identified as ex vivo resistant failed to respond. The DiSC assay can accurately identify a subgroup of patients resistant to cladribine...
  5. ncbi Effect of interleukin-2 on CD95 (Fas/APO-1) expression in fresh chronic lymphocytic leukaemia and mantle cell lymphoma cells: relationship to ex vivo chemoresponse
    A G Bosanquet
    Bath Cancer Research, Wolfson Center, Royal United Hospital, U K
    Anticancer Res 19:5329-34. 1999
    ..The link between CD95-induction and ex vivo drug resistance may point to a clinically resistant subset of CLL patients...
  6. ncbi Bax expression correlates with cellular drug sensitivity to doxorubicin, cyclophosphamide and chlorambucil but not fludarabine, cladribine or corticosteroids in B cell chronic lymphocytic leukemia
    A G Bosanquet
    Bath Cancer Research, Wolfson Centre, Royal United Hospital, Bath, UK
    Leukemia 16:1035-44. 2002
    ....
  7. ncbi Ex vivo cytotoxic drug evaluation by DiSC assay to expedite identification of clinical targets: results with 8-chloro-cAMP
    A G Bosanquet
    Bath Cancer Research Unit, School of Postgraduate Medicine, University of Bath, Royal United Hospital, UK
    Br J Cancer 76:511-8. 1997
    ..The results highlight the clinical potential of 8-Cl-cAMP, point to several new phase I, II and III trial possibilities and provide a rationale for the inclusion of ex vivo cytotoxic drug evaluation in the drug development process...
  8. ncbi Ex vivo therapeutic index by drug sensitivity assay using fresh human normal and tumor cells
    Andrew G Bosanquet
    Bath Cancer Research, Royal United Hospital, Bath BA1 3NG, UK
    J Exp Ther Oncol 4:145-54. 2004
    ..We conclude that further laboratory and clinical evaluation is required but the derived ex vivo therapeutic index could enhance choice of chemotherapy by reducing toxicity and/or improving efficacy...
  9. ncbi In B-CLL, the codon 72 polymorphic variants of p53 are not related to drug resistance and disease prognosis
    Isrid Sturm
    Department of Hematology, Oncology and Tumor Immunology, University Medical Center Charite, Campus Berlin Buch, Berlin, Germany
    BMC Cancer 5:105. 2005
    ..Here, we address the functional relevance of the codon 72 single nucleotide (SNP) polymorphism for cell death sensitivity following exposure to clinically employed cytotoxic drugs and gamma-irradiation...
  10. ncbi Silencing of APAF-1 in B-CLL results in poor prognosis in the case of concomitant p53 mutation
    Isrid Sturm
    Department of Hematology and Oncology, Charite, Campus Virchow Medical Center, Humboldt University, Berlin, Germany
    Int J Cancer 118:2329-36. 2006
    ..Nevertheless, a poor prognosis was observed in patients with loss of APAF-1 expression and additional p53 mutation. Thus, loss of APAF-1 may become relevant when additional core apoptosis signaling components are disrupted...